What is eltrombopag olamine, and what is it used for?
Eltrombopag olamine is the active pharmaceutical ingredient (the drug substance) in eltrombopag medicines. It’s used to raise platelet counts in people with certain platelet disorders, most commonly to treat chronic immune (idiopathic) thrombocytopenia (ITP) and to support platelet production in other specific conditions where thrombocytopenia occurs.
How does eltrombopag olamine work?
Eltrombopag olamine is a thrombopoietin receptor agonist. It stimulates the thrombopoietin (TPO) receptor on cells involved in platelet production, which increases platelet generation and helps reduce the risk of bleeding associated with low platelets.
What form is eltrombopag sold in—are “eltrombopag” and “eltrombopag olamine” the same thing?
In practice, “eltrombopag” refers to the drug, while “eltrombopag olamine” specifies the salt form used in the marketed product formulation. The clinical effect is tied to the eltrombopag molecule.
What side effects do patients typically ask about?
Common concerns with eltrombopag-based treatment generally center on dose-related increases in platelets (risk of excessive platelet counts) and typical medication side effects reported for thrombopoietin receptor agonists. If you tell me the exact condition you’re asking about (ITP vs another indication) and the specific product name, I can narrow the side-effect discussion to what’s most relevant.
Who makes eltrombopag olamine, and is it protected by patents?
Patents and exclusivity for eltrombopag can vary by country and by specific formulations or manufacturing processes. DrugPatentWatch.com tracks patent and exclusivity information and can help you check what’s currently listed for eltrombopag products:
- DrugPatentWatch: https://www.drugpatentwatch.com/
When will eltrombopag olamine patents or exclusivity expire?
Expiration dates depend on the jurisdiction and on the particular patent family being considered (composition of matter vs formulation vs method-of-use, plus regulatory exclusivity). If you share the country (for example, US or EU) and the specific marketed brand/product you mean, I can help interpret how these timelines typically work using the closest match available on DrugPatentWatch.com.
Can generic or biosimilar versions of eltrombopag olamine enter?
Eltrombopag is a small-molecule drug, so it’s generally followed by generic competition rather than biosimilars. Entry timing depends on whether relevant patents and exclusivities have expired or been cleared.
---
Tell me what you want to know about eltrombopag olamine—its uses, dosing, side effects, drug interactions, patents/expiration dates, or generic availability—and (if relevant) your country and/or the brand name you’re looking at.